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CObjectives: To find preferences for treatment expressed by lupus pa-
tients and physicians (whowere asked to assume they have lupus) and
to explore if certain variables explain these preferences.Methods: One
hundred seventy-two patients and 202 physicians were interviewed
using a lupus nephritis decision board that describes the treatment
options and their potential benefits and risks. Clinical and sociodemo-
graphic variables were collected. Participants were asked to indicate
their preferred treatment and provide justification for their choice. De-
scriptive statistics, t tests, and Pearson’s chi-square tests were used to
determine the significance of differences in the decisions made by the
two groups. A logistic regressionmodel determined which factors con-
tributed to treatment decisions. Results: The average age of study par-
ticipants was 34  8 years for patients and 31  7 years for physicians.
Sixty-eight percent of patients and 96% of physicians (P  0.001) se- O
e no
al Un
al So
doi:10.1016/j.jval.2011.05.015ected the oral option. Patients and physicians justified their choice of
reatment using different arguments (P  0.001 in each case). Logistic
regression showed that risk potential (P  0.001) and a history of joint
nvolvement (P 0.011) were the arguments usedmost often to explain
patient’s decision and the risk of side effects was most relevant
mong physicians (P  0.001). Conclusions: Using a decision board,
atients and physicians were found to have different preferences for
reatment when faced with the same treatment options. Further, the
ariables that influence their preferences are different.
eywords: decision aids, patient preference, shared decision making,
ystemic lupus erythematosus.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The growing involvement of patients in their health care decisions
has given them a more active role in the patient–physician rela-
tionship [1,2]. Many studies have looked at this theme and show
that different factors will influence patient preferences for their
health care [3–6]. Some studies have looked at the relevance of
parameters such as pain, clinical history, socioeconomic context,
and the willingness to accept the risk that clinical decisionsmight
have adverse outcomes [6–9]. Many authors have also pointed to
discrepancies between patient and physician preferences in terms
of the therapeutic handling of different diseases, including the
techniques used to approach this point [10,11]. These issues are
parameters that must be looked at from the point of view of pref-
erence-based medicine [5–11].
Systemic lupus erythematosus (SLE) is a chronic inflammatory
autoimmune disease of varying progress and prognosis [12]. Lupus
nephritis (LN) is the renal complication of SLE. It occurs in 40% to 60%
ofpatientsat somestageof thedisease [12,13]. Survivalhas increased
in recent decades due to a better understanding of the mechanisms
of the disease and the therapeutic arsenal available [12,14]. The tar-
get of treatment is to promote remissionof renal disease and impede
its progression to endstage renal disease [12,13]. All of the prognostic
studies have identified LN as a predictor of a negative outcome [12–
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Published by Elsevier Inc.14]. Therapeutic handling of LN remains controversial due to the
different risks and benefits resulting from the use of the immuno-
suppressive drugs available to treat LN [12–14]. Several studies have
been exploring patient preferences on the context of lupus disease.
However theyusually donotuseadecision tool tohelp theprocess of
decision making [15–21].
A decision support tool, such as a decision board (DB), displays
a number of clinical issues and the consequences of each option to
enable solving the issue using a process that is both standardized
and free of bias [22]. The DB is a simple tool that displays more
than one therapeutic option to be valued and decided on [22–25]. It
is low cost and can be easily updated.
The development and validating of a Brazilian DB for LN for
patients in Brazil was the first step in our study and has been
described in a previous article [24]. Although several studies have
attempted to assess the existence of discrepancies between phy-
sician and patient preferences regarding the same health care is-
sue, most have used physicians who specialize in the disease in
question [15–21]. In our study, we deliberately did not use rheu-
matologists for the reasons explained in more detail below. The
objectives of this study were: 1) to find out the preferences for
treatment expressed by SLE patients and by physicians who were
asked to assume that they themselves had SLE, when faced with
two options to treat LN using the Brazilian DB for LN, and 2) to
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iversity of São Carlos, Medicine Department, Washington Luis
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
S142 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) S 1 4 1 – S 1 4 6explore if certain variables explain these preferences and if these
variables differ between the patients and the physicians.
Materials and Methods
This was a cross-sectional study [26]. Patients were selected con-
secutively on the date they were seen at a university tertiary hos-
pital clinic, which is an authority in the country on the care of
complex diseases like SLE. Over the period of one year, patients
and physicians were invited to take part in the study.
Nonrheumatologist physicians were selected from the person-
nel files of the same institution. An Email message was sent to
each of these physicians describing the nature of the study and
inviting them to come in for an interview. Those who agreed to
participate and met the criteria for selection were included in the
study. Interviewswith consenting physicianswere scheduled dur-
ing normal working hours at the hospital.
The following criteria were used to include patients: women
between ages 18 and 50 years with a 12-month or longer diagnosis
of SLE according to the modified classification criteria published
by the American College of Rheumatology and any clinical mani-
festation of the disease. In addition, patients had to be able to read
and write, according to their own statement, agree to participate
in the study, and sign a statement of free and informed consent.
Patients presenting active lupus psychosis or any formof cognitive
Fig. 1 – Schematic representation of the decision board. Initi
with only the subtitles visible. The content is filled out durin
disease information, with an emphasis on lupus nephritis.
administration, likelihood of remission and a list of the eigh
highest prevalence. The interviewee then selects, from the l
bothersome. (C) Data on the probability of experiencing each
as the most undesirable.disability that would make it difficult for them to understand thequestionnaires were excluded, as were patients whose records
were unavailable at the time of the interview.
The following criteria were used to include physicians: female
academic physicians, practitioners, and physicians in training.
Rheumatologists were excluded from the study to avoid a bias
based on specific knowledge of the disease or the practices in the
services they work for. We only recruited female physicians be-
cause the disease primarily affects women.
The LNDBwas used during individual interviews [25]. The con-
tent was presented and added to during the course of the inter-
view (Fig. 1). At the beginning of the interview participants were
given a summary presentation of the disease. Following this, they
were given information on the treatment options (Option 1- oral
treatment, or Option 2 - intravenous treatment), including meth-
ods of administration, the chances of remission, and a list of the
eight most prevalent side effects described in the literature. We
did not include the name of the drugs to avoid bias. Option 1 (oral)
referred to therapy with mycophenolate mofetil, and Option 2 to
therapy with intravenous cyclophosphamide. Study participants
were asked to select the three side effects that most bothered
them out of the list of eight. In the last phase of the DB, partici-
pants were told the probability of each of the selected side effects
for each treatment option. Following the standard presentation,
the content was reviewed and interviewees were asked to select
one of the treatment options. After this they were asked to justify
only Chart A if fully exposed. Charts B and C are shown
e course of the interview. (A) Summary presentation of
description of the treatment options: method of
tential side effects that the literature reports as having the
f eight side effects, those which she finds most
he three side effects selected by the individual intervieweeally,
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risk/benefit trade-off, and practicality. Risk justifications were
those based on the probability of each of the three side effects for
each treatment option. Effectiveness justifications were those
where participants justified their treatment choice based on the
probability of disease remission. Risk/benefit trade-off justifica-
tions were those where patients, when choosing their preferred
option, tried to consider all of the characteristics of both treatment
options (i.e., their potential risks and effectiveness). Practicality
justifications were those where the most important factor in
choosing the treatment was how the drug was administered and
how it would affect the interviewee’s day-to-day activities [15–25].
The methodology used to categorize the justifications was pre-
sented in an article on developing and validating the Brazilian LN
DB [25]. Following the DB presentation, patients were asked to fill
out the clinical and health related quality of life questionnaire.
The clinical questionnaires used were Systemic Lupus Erythema-
tosus Disease Activity Index [SLEDAI] [27], and Systemic Lupus
International Collaborating Clinics/American College of Rheuma-
tology Damage Index (SLICC–DI) [28]. Health-related quality of life
as assessed using the Medical Outcomes Study 36-Item Short-
orm Health Survey (SF-36). Previous studies had already trans-
ated and tested the validity of the Portuguese language version of
his tool [29,30]. Socioeconomic variables were assessed using the
razilian Economic Classification Criterion (BECC) questionnaire,
validated tool used to classify people into socioeconomic cate-
ories (ranging from A to E, with A being the highest) [31]. In our
study we wanted to test the hypothesis that patients and physi-
cianswill choose different treatments for LNwhen presentedwith
the same clinical scenario using the DB. This hypothesis was for-
mulating based on the following premises: 1) the socioeconomic
and cultural contexts are different for the physician and patient
groups included in the study; and 2) physicians tend to have some
technical information about the disease and a different frame of
mind in termof understanding of diseases in general. By excluding
rheumatologists we believe we came as close as possible to con-
trasting the medical approach with the lay person approach to
assessing the value of a treatment.
Initially we assessed the preferences of each group for treat-
ment (ie, choice of preferred treatment) following the DB presen-
tation.We then tested if a statistical difference between treatment
preferences exists, after whichwe tried to find outwhich variables
might explain the treatment preferences of each group.
The following variables were used to test the hypothesis: 1)
decision variables (i.e., side effects selected, treatment decision,
and justification); 2) socioeconomic variables (i.e., income, the
BECC, and years of schooling); 3) clinical variables (i.e., severity). In
this study, we defined severity as two or more of the following:
prior and/or current use of cyclophosphamide; prior and/or cur-
rent use of other immunosuppressive agents; increased disease
activity defined as an SLEDAI score of eight ormore; and increased
chronicity, defined as an SLICC-DI score of five or more. Severity
was adopted as a dichotomous variable.
The project was approved by the Committee for Ethics in Re-
search of our institution.
Statistical analysis
This study belongs to a larger one. We developed and tested a DB
and a willingness-to-pay tool to assess strengh of preference. The
sample was calculated based on prior similar studies and an equal
distribution of the values to be offered in the willingness-to-pay
survey. The estimated sample was 150 interviewees for each
group [28,32]. The descriptive analysis summarizes the qualitative
and quantitative variables as appropriate. Patient and physician
results were compared using Pearson’s chi-square and Student t
tests [32]. For the purposes of this analysis, side effects were fgrouped into risk of death that was also presented as a dichoto-
mous variable (yes/no).
Univariate analyses were completed to identify associations
between variables and LN treatment decisions. Logistic regression
analyses assessed which factors influence the treatment decision
in each group. We assumed that Option 1 and Option 2 are the
dependent variables. As explanatory variables we included side
effects, justification for the option selected, socioeconomic vari-
ables, years of schooling, clinical severity variables (yes/no), and
quality of life (SF-36 domains) [32,33]. Only associations found to
be significant with univariate analyses were included in the logis-
tic regression [30,31]. For all statistical tests we considered a level
of significance of 5% or lower [32,33]. All of the statistical analyses
were conducted using SPSS version 13.0 (SPSS Inc., Chicago, IL).
Results
We interviewed 172 patients and 202 physicians during 1 year. The
average age was 34  8 years for patients and 31  7 years for
physicians. All of the patients approached agreed to participate in
the study and 8%of the physicians approached refused, all of them
in training and claiming not to have time to participate. Everyone
who participated in the survey provided data. Most of the patient
group was made up of mulatto (i.e., Brazilian mixed race [35,36])
persons (45%) and most of the physician group (67%) was white.
Demographic, quality of life, and clinical characteristics are de-
scribed in Tables 1, 2, and 3, respectively. Regarding the BECC dis-
tribution, 76% of patients were classified as C and D and 18% as B2.
In the physician group, the BECC distribution was class A2 (33.2%),
followed by B1 (24.8%), and A1 (20.3%) (Table 1). All of the SF-36
domain scores were lower for patients than physicians (P  0.001
Table 1 – Demographic and socioeconomic
characteristics of the study population*.
Patients Physicians
1. Age – average (SD) 34.3 (8) 31.0 (7)
2. Race – N (%)
Whtie 68 (39.5) 136 (67.0)
Non-white 104 (60.5) 68 (33.0)
3. Marital status (N%)
Single 58 (33.5) 147 (73.0)
Married 95 (55.2) 50 (25.0)
Divorced/separated 16 (9.3) 0 (0.0)
Windowed 2 (1.1) 2 (1.0)
Other† 1 (0.5) 3 (1.0)
4. No. of children
0–1 103 (59.1) 185 (91.6)
2–3 62 (35.9) 16 (7.9)
4 7 (4.0) 1 (0.5)
5.BECC (income, in
US$ equivalent)
A1 (3000,00) 0 (0.0) 41 (20.3)
A2 (2100,00) 2 (1.2) 67 (33.2)
B1 (980,00) 7 (4.1) 50 (24.8)
B2 (550,00) 31 (18.0) 32 (15.8)
C (327,00) 87 (50.5) 12 (5.9)
D (212,00) 44 (25.5) 0 (0.0)
E (103.5,00) 1 (0.6) 0 (0.0)
P  0.001 for all comparisons.
BECC, Brazilian Economic Classification Criterion.
* Values are the number (%) unless otherwise indicated.
† Other: Assigned (government donation, squatter’s rights,
UNIFESP resident housing).or each comparison). The average time spent on the DB was 20
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frequency of the three worst side effects selected by patients was:
cancer caused by the drug (44.2%), hair loss (21.6%), and severe
infection (19.1%). Among physicians the order of selected side ef-
fects was cancer caused by the drug (45.5%), severe infection
(33.1%), and sterility (12.5%). The difference in side effects selected
by the two groupswas statistically significant (P 0.001), as shown
n Table 4. Option 1 was the preferred treatment choice by 68% of
atients and 98% of physicians (P 0.001). Patients and physicians
ustified their decision based on risk (47.7% and 68.9%), effective-
ess (12.2% and 2.0%), risk/benefit trade-offs (2.3% and 22.3%), and
racticality (37.8% and 5.9%). Analyses show these differences are
Table 2 – Health-related quality of life characteristic of
the study population.
Patients
(n  172)
Physicians
(n  202)
Median
(standard
error)
Median
(standard
error)
Functional capacity 67,99 (1,91) 91,98 (0,63)
Physical issues 67,08 (2,07) 88,59 (1,33)
Pain 58,68 (1,92) 80,07 (1,37)
Overall health 54,87 (1,69) 82,08 (1,01)
Vitality 53,16 (1,77) 62,03 (1,23)
Social aspects 64,45 (2,19) 79,19 (1,46)
Emotional aspects 68,2 (2,16) 85,33 (1,33)
Mental Health 55 (1,82) 71,81 (1,13)
Note: For all comparisons, P  0.001.
SF-36, The Medical Outcomes Study 36-Item Short-Form Health
Survey.
Table 3 – Clinical characteristics of lupus erythematosus
patients included in the study (N = 172).
Characteristic n %
1. Duration of disease (y)
1 9 5.2
1–6 67 38.9
7–13 52 30.2
14 37 21.5
2. Lupus nephritis
Yes 129 75.0
3. Cyclophosphamide use prior to or
during the study
Yes 94 55.0
4. Immunosuppressant drug use prior to
or during the study
Yes 129 75.0
5. ACR classification criteria
1. Malar rash 21 12.2
2. Discoid rash 11 6.4
3. Photosensitivity 27 15.6
4. Oral ulcer 6 3.5
5. Arthritis 144 83.7
6. Serositis 45 26.0
7. Renal disorder 77 44.8
8. Neurological disorder 16 9.3
9. Hematological disorder 36 21.0
10. Immunological disorder 105 61.0
11. Anti-nuclear antibody 165 96.0ACR, American College of Rheumatology.tatistically significant in each case (P  0.001) (Table 4). Based on
univariate analysis, the variables selected for the multivariate
atient model were: cancer, severe infection, decision justifica-
ion, SLEDAI, skin involvement, joint involvement,maternity (yes/
o), number of inhabitants, socioeconomic class, income, and SF-
6. The final model was adjusted excluding variables step by step
o arrive at a reduced model. Multivariate analysis shows that
atient decisions were guided primarily by the potential risk
osed by the drug, represented by a risk based justification, com-
ared to an effectiveness-based justification (P  0.001; odds ratio
1.8; 95% confidence interval 8.2–122.9) or a practicality based jus-
ification (P  0.001); OR 6.0; 95% CI 2.5–14.2). Patients with prior
oint involvement were less likely to select Option 1, compared
ith patients with no joint involvement (P  0.011; OR 5.3; 95% CI
.4–19.5) (Table 5).
In the physician group, the same explanatory variables were
sed to build the univariate model, with the exception of the clin-
cal variables. This model showed that physicians who justified
heir decision based on risk tended to select Option 1, compared to
Table 4 – Distribution of patient and physician
selections regarding the scenarios presented by the
decision board*.
Characteristics Patients
(n  172)
Physicians
(n  202)
P
1. Side-effects selected – N (5)
Latrogenical cancer 137 (79.7) 196 (97.0) 0.001
Sterility 42 (24.4) 131 (64.9) 0.001
Severe infection 116 (67.4) 168 (83.2) 0.001
Mild infection 14 (8.1) 5 (2.5) 0.013
Nausea 39 (22.7) 6 (3) 0.001
Vomiting 31 (18) 22 (10.9) 0.049
Diarrhea 38 (22.1) 24 (11.9) 0.008
Hair loss 96 (55.8) 53 (26.2) 0.001
2. Treatment decision
Option 1 (Yes) 117 (68%) 196 (98%) 0.001
3. Treatment decision
justification
Risk 82 (47.6) 141 (69.8) 0.001
Effectiveness 21 (12.0) 4 (1.9) 0.001
Risk-benefit trade-off 4 (2.0) 45 (22.4) 0.001
Practicality 66 (38.) 12 (5.9) 0.001
* Values are number (%) unless otherwise indicated.
Table 5 – Logistic regression model to assess the factors
that influence lupus nephritis treatment preferences
among real patients and physicians exposed to the
decision board scenarios.
Variable* P Odds
ratio
95%
Confidence
interval
Patients
Justification
Risk/effectiveness 0.001 31.8 8.2 122.9
Risk/practicality 0.001 6.0 2.5 14.2
Joint involvement 0.011 5.3 1.4 19.5
Socioeconomic category
C/AB 0.073 0.3 0.11 1.1
D/AB 0.024 0.2 0.07 0.8
Physicians
Risk/practicality 0.007 64 3.12 1332* Dependent variable: Option 1.
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4; 95% CI 3.1–1332). (See Table 5.) Age can also influence the de-
ision: the older the study participant the more likely she was to
elect Option 1 (P  0.08; OR 2.28; 95% CI 0.88–5.8).
Discussion
This study addresses the preferences for treatment of two differ-
ent groups facing the same scenario. Both groups consisted of
individuals of the same sex and of a similar age group. The other
demographic characteristics are different for the two groups,
among them socioeconomic level and BECC scores (Table 1) [31].
The health-related quality of life profile also yielded different re-
sults for both groups. The patient group had the lowest SF-36
scores in all domains, probably as a result of the disease itself
(Table 2). Because the institutionwas a tertiary center, the severity
of the disease reflected this, as shown in Table 3. The two groups
selected different side effect as being more important (Table 4).
Regarding the treatment options, both groups tended to prefer
Option 1. Results showed that the decisions were based on differ-
ent justifications (P  0.001), which were a reflection of what is
important for each interviewee whenmaking treatment decisions
(Table 5).
We asked physician to imagine they were patients (i.e., to
imagine that they have LN). This strategy has strengths and limi-
tations. The strengths lie in the fact that, by considering them-
selves patients, potentially the physicians will make their deci-
sions from the point of view of a patient. Different from other
studies that have assessed the preference of physicians and pa-
tients, we tried to assess the physician choice, encouraging them
to place themselves on the other side and make their decisions
accordingly [15–21]. By excluding rheumatologists, we avoid deci-
sions that are influenced by clinical practice and well known evi-
dence. In this way, we can elicit physician preferences and under-
stand how they make their own health care decisions. This
informationmay help us understand howmedical knowledge and
training can influence choices. This in turn can contribute to the
design of education strategies that can help both patients and
physicians communicate and deliberate while attempting to
choose the best treatment for the patient [15–25].
This study was structured to simulate the practical clinical re-
ality of the institution where it was developed. A previous study
done in Brazil explored patients’ and physicians’ perceptions
about rheumatoid arthritis care. A study by Ferraz et al. [34] ob-
erved that patient and rheumatologists had different opinion
bout the health care provided. This study had a limitation that
he answers provided by the rheumatologists who participated in
he study were based on the guidelines used during that period of
ime rather than on what really happened [18–21,34].
A limitation of our study is that decisions made based on a
ypothetical scenario may not necessarily reflect the decisions
hat would be made in a real situation. We believe, however, that
he strengths outweigh the potential limitation. In addition, pa-
ients included in the study faced a hypothetical situation because
new theyweremaking a decision as part of a scenario, and not an
ctual decision regarding their own treatment. This being the
ase, both groups faced hypothetical situations [15–21].
Regarding the side effects chosen, although the side effect
ost often selected as being the worst was cancer by both groups
44% for patients and 45% for physicians), the rest were quite dif-
erent (P 0.001).We still do not understand the factors that could
nfluence these decisions [25]. Other studies that assess patient
references suggest similar results, although none made use of a
upport tool. There is a need for studies to explore this area [25].
As a measure of agreement between patients and physicians,
appa test was used to compare both groups’ choices regarding
he three side effects chosen and the final decision. For the threeide effects chosen, Kappa results were 0.334, 0.202, and 0.220 (P
.001), respectively. In respect to the final decision, Kappa coeffi-
ient was 0.757 (P  0.001).
Both groups tended to prefer Option 1. This was, however,
tronger among physicians and it was statistically significant
98% vs. 68% for patients; P 0.001). There are also significant
ifferences in their justifications (P  0.001). Also, this study
howed that both groups have in common the fact that the vari-
ble “decision justification” was the one that best explained the
ecision regarding treatment options. It can allow us to reflect
hat, even if the justifications used by the two groups were differ-
nt, their influence on the decisions made reflect their concerns
egarding the potential consequences of these decisions. These
ndings also show that different factors influence patient and
hysician decisions, as shown in the decision justifications [26,35–
4], and may be one of the factors explaining the miscommunica-
ion observed in patient–physician encounters [35,36,43–45]. Re-
arding the other factors that influence preferences, study results
lso show that joint involvement and possibly socioeconomic
lass influence patient treatment decisions. These variables may
eflect the impact of the chronic nature and how this influences
atient decisions. This interpretation is speculative. The variables
hat explain what influences patient preferences are far from be-
ng completely understood and further research is called for to
xplore this issue. Among physicians, household income and
ECC scores did not influence treatment decision. These datamay
eflect the homogeneous socioeconomic and cultural character of
his group compared to the patient group, which is socioeconom-
cally more diverse and made up predominantly of persons in so-
ioeconomic categories C, D, and E [31]. One issue that may have
nfluenced this group’s decision was the likelihood of the selected
ide effects. This strategy enabled making up a scenario of a se-
erity proportional to the events mentioned [37–41]. Our results
how that physician and patient decisions are influenced by dif-
erent factors, leading to potential discrepancies when facing the
ame issue to be assessed, namely the treatment of LN. Consider-
ng the chronic nature of SLE and its clinical peculiarities, wemust
uestion if such differences compromise communication between
hysician and patient in clinical practice, leading to poor treat-
ent compliance [37–45].
Conclusions
Physician andpatient decisions are influenced by different factors,
leading to potential discrepancies when facing the same issue to
be assessed. Treatment choice has to be discussed with patients,
because individual preference seems to be determined by per-
sonal attitudes toward safety and convenience, by past experi-
ence, and by the perception of current disease status.
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